OpenAI Explores Massive Funding Round at $750 Billion Valuation 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
BOSTON, Aug. 04, 2017 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Canaccord Genuity 37th Annual Growth Conference in Boston on Wednesday, August 9, 2017 at 1:30 p.m. Eastern Time.
A live webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617-466-3511 [email protected]
